Latest Protease inhibitors Stories
-- New all-oral, short-course (12 weeks), interferon-free treatment available in Canada for genotype 1 hepatitis C patients -- In Phase 3 clinical trials, HOLKIRA
- In Phase 3 clinical trials, VIEKIRA PAK cured 95-100 percent of hepatitis C patients, with less than 2 percent of patients experiencing virological failure NORTH CHICAGO, Ill., Dec.
SAN DIEGO, Dec. 2, 2014 /PRNewswire/ -- Aethlon Medical, Inc.
GENEVA, December 1, 2014 /PRNewswire/ -- Licence will support the work of the recently launched Paediatric HIV Treatment Initiative (PHTI) to Develop Better Adapted
- In adult patients co-infected with genotype 1 (GT1) hepatitis C virus (HCV) infection and human immunodeficiency virus (HIV) type 1 infection, TURQUOISE-I demonstrated sustained virologic response
-- Studies focused on patients where there is a high unmet need today or anticipated in the near future -- BOSTON, Nov.
--Expanded indication includes both treatment-naive and treatment-experienced adult patients with or without cirrhosis-- TITUSVILLE, N.J., Nov.
Data from 25 accepted abstracts include results from: NORTH CHICAGO, Ill., Oct.
BEERSE, Belgium, September 29, 2014 /PRNewswire/ -- CHMP also issues two label extensions for darunavir Janssen-Cilag International NV (Janssen)
MarketOptimizer.org adds “PharmaPoint: Hepatitis C Virus – Global Drug Forecast and Market Analysis to 2022 – Event-Driven Update” to its store.
- The act of sweetening by admixture of some saccharine substance.